Mainz Biomed NV Form 4 insider transactions

William J Caragol, Chief Financial Officer of Mainz Biomed N.V., received 212,500 shares of common stock on August 11, 2026.

David E. Lazar, Chief Executive Officer, a Director and 10% owner of Mainz Biomed N.V., reported multiple transactions in common stock on August 5, 2026.

Peter O'Rourke, a Director of Mainz Biomed N.V., received 191,860 shares of common stock on July 22, 2026.

David Natan, a Director of Mainz Biomed N.V., received 191,860 shares of common stock on July 22, 2026.

William J Caragol, Chief Financial Officer of Mainz Biomed N.V., received 212,500 shares of common stock on July 22, 2026.

Louis R. Buffalino, a Director of Mainz Biomed N.V., received 425,000 shares of common stock on July 22, 2026.

Avraham Ben-Tzvi, a Director of Mainz Biomed N.V., received 112,859 shares of common stock on July 22, 2026.

Avraham Ben-Tzvi, a Director of Mainz Biomed N.V., received 112,259 shares of common stock on July 31, 2026.

Peter O'Rourke, a Director of Mainz Biomed N.V., received 190,840 shares of common stock on July 31, 2026.

David Natan, a Director of Mainz Biomed N.V., received 190,840 shares of common stock on July 31, 2026.

William J Caragol, Chief Financial Officer of Mainz Biomed N.V., received 212,500 shares of common stock on July 31, 2026.

Louis R. Buffalino, a Director of Mainz Biomed N.V., received 425,000 shares of common stock on July 31, 2026.

Quantum Cyber N.V. director Peter O'Rourke acquired 112,859 stock options with an exercise price of $1.45.

Quantum Cyber N.V. director Avraham Ben-Tzvi reported the acquisition of 137,141 ordinary shares on May 8, 2026.

Director David Natan reported the acquisition of 137,141 ordinary shares of Quantum Cyber N.V. on May 8, 2026.

CEO David E. Lazar acquired 2,000,000 additional preferred shares in Quantum Cyber N.V. following shareholder approval of key corporate actions.

Mainz Biomed N.V. Director David E. Lazar acquired $3 million in preferred shares, with an additional $3 million pending, contingent on significant stockholder approvals including a reverse stock split and board changes.

Mainz Biomed N.V. Chief Financial Officer William J Caragol was granted 290,000 ordinary shares under the company's 2025 Omnibus Incentive Plan.

Mainz Biomed N.V. Director Heinrich Dreismann was granted 45,000 restricted ordinary shares under the company's 2025 Omnibus Incentive Plan.

Mainz Biomed N.V. Director Gregory J. Tibbitts acquired 45,000 ordinary shares through a restricted stock grant, increasing his beneficial ownership to 55,875 shares.

Mainz Biomed N.V.'s CEO, Guido Baechler, was granted 440,000 restricted ordinary shares under the company's 2025 Omnibus Incentive Plan.

MAINZ BIOMED N.V. Director and 10% Owner Kevin Michael Donahue filed an amendment detailing a planned acquisition of 685,000 shares of common stock at $1.51 per share.

MAINZ BIOMED N.V. Director and 10% owner Kevin Michael Donahue acquired 643,850 shares of common stock for $402,000.